This brand name is authorized in Hong Kong SAR China, Singapore.
The drug ZADAXIN contains one active pharmaceutical ingredient (API):
1
|
UNII
W0B22ISQ1C - THYMALFASIN
|
|
Thymalfasin is a synthetic analogue of thymosin-alpha-1. T-helper and cytotoxic/suppressor T-cell populations are targets of thymosin activity. Thymosin-alpha-1 has been shown to increase the efficiency of antigen presentation by macrophages and to be an endogenous modulator of alpha-thrombin activity. It is used alone or with interferon as an immunomodulator for the treatment of chronic hepatitis B and hepatitis C. Thymalfasin is also used for the treatment of chemotherapy-induced immunosuppression, and to enhance the efficacy of influenza and hepatitis B vaccines in immunocompromised patients. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| L03AX | Other immunostimulants | L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| HK | Department of Health Drug Office | 50907 |
| SG | Health Sciences Authority | 07483P |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.